This study investigated the prevalence of potentially undiagnosed fibrotic metabolic dysfunction-associated steatohepatitis (MASH) within a general population. The aim was to characterize individuals at risk of MASH using the Fibrotic NASH Index (FNI) and to compare outcomes between risk groups and those with established MASH.
Patient Data and Risk Stratification
Data was collected from patients in Stockholm, Sweden, between 2010 and 2020, and from specialist care records between 1998 and 2022. Patients were classified as high risk based on FNI scores and the presence of cardiometabolic risk factors, and low risk based on FNI scores without these factors. Individuals with established MASH were identified by ICD-10 code (K75.8).
Key Clinical Findings
Analysis of FNI data revealed that 23% of patients were considered high risk and 39% were considered low risk. Among patients with established MASH, major adverse liver outcomes (MALO) were more common than in high-risk FNI patients. The rate of incident MALO was higher in diagnosed MASH patients compared to the high-risk FNI group. The rate of major adverse cardiovascular events (MACE) was also higher in high-risk FNI patients compared to low-risk FNI patients. The study highlighted a significant burden of potentially undiagnosed at-risk MASH within the population. Almost half of patients with established MASH already exhibited MALO at baseline, emphasizing the importance of earlier diagnosis.